Idiopathic pulmonary fibrosis (IPF) is entering an important new chapter, as highlighted in a newly published BioCentury article that underscores the growing momentum behind next-wave therapeutics.
We are pleased to have our CMO, Jonas Hallén, included in that discussion as we advance CAL101, our first-in-class S100A4 targeting mAb. We continue to rapidly enroll patients in our Phase II AURORA study in IPF.
It is encouraging to see the appreciation for the need for, and underlying body of evidence supporting, new treatment options for IPF, which also informs progress in other fibrotic and inflammatory diseases.